Oncology BRA Methodology Guide

The oncology benefit-risk landscape has been transformed by the emergence of checkpoint inhibitors, targeted therapies, and combination regimens. Traditional BRA approaches struggle with the complexity of oncology safety profiles — immune-related adverse events spanning multiple organ systems, delayed toxicity patterns, and the challenge of quantifying benefit in diseases with heterogeneous patient populations. This guide presents ArcaScience's AI-driven methodology purpose-built for oncology BRA, integrating data from 47+ global sources including FAERS oncology-specific signals, EudraVigilance SUSAR reports, and published clinical trial data across 200+ oncology compounds.

Key innovations include automated detection of immune-related adverse event (irAE) patterns across checkpoint inhibitor classes, quantitative benefit scoring using progression-free and overall survival endpoints, and comparative safety profiling across therapeutic alternatives. The platform's oncology-specific AI models achieve 96% accuracy in MedDRA coding for oncology adverse events and 91% precision in irAE causality assessment — substantially outperforming general-purpose approaches.